AU2001241533A1 - A universal vaccine and method for treating cancer employing telomerase reverse transcriptase - Google Patents

A universal vaccine and method for treating cancer employing telomerase reverse transcriptase

Info

Publication number
AU2001241533A1
AU2001241533A1 AU2001241533A AU4153301A AU2001241533A1 AU 2001241533 A1 AU2001241533 A1 AU 2001241533A1 AU 2001241533 A AU2001241533 A AU 2001241533A AU 4153301 A AU4153301 A AU 4153301A AU 2001241533 A1 AU2001241533 A1 AU 2001241533A1
Authority
AU
Australia
Prior art keywords
cells
peptide
htrt
ctl
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001241533A
Other languages
English (en)
Inventor
Maurizio Zanetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California Berkeley
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22669572&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001241533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California Berkeley, University of California, San Diego filed Critical University of California Berkeley
Publication of AU2001241533A1 publication Critical patent/AU2001241533A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2001241533A 2000-02-15 2001-02-15 A universal vaccine and method for treating cancer employing telomerase reverse transcriptase Abandoned AU2001241533A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18268500P 2000-02-15 2000-02-15
US60/182,685 2000-02-15
USNOTGIVEN 2000-12-14
PCT/US2001/005143 WO2001060391A1 (en) 2000-02-15 2001-02-15 A universal vaccine and method for treating cancer employing telomerase reverse transcriptase

Publications (1)

Publication Number Publication Date
AU2001241533A1 true AU2001241533A1 (en) 2001-08-27

Family

ID=22669572

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001241533A Abandoned AU2001241533A1 (en) 2000-02-15 2001-02-15 A universal vaccine and method for treating cancer employing telomerase reverse transcriptase

Country Status (5)

Country Link
US (2) US7388071B2 (enExample)
JP (1) JP2004527449A (enExample)
AU (1) AU2001241533A1 (enExample)
CA (1) CA2399816A1 (enExample)
WO (1) WO2001060391A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
EA199900355A1 (ru) 1996-10-01 2000-08-28 Джерон Корпорейшн Теломераза обратная тринскриптаза
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
GB0105238D0 (en) * 2001-03-02 2001-04-18 Norsk Hydro As Vaccines
US8663645B2 (en) * 2005-05-09 2014-03-04 Vaxon Biotech Use of native peptides and their optimized derivatives for vaccination
JP2009523817A (ja) * 2006-01-19 2009-06-25 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒトテロメラーゼ逆転写酵素ペプチド
EP2453243A1 (en) * 2010-11-11 2012-05-16 Cosmo S.p.A. Method for the diagnosis and/or follow up of the evolution of a tumor
CA2954892A1 (en) 2016-01-19 2017-07-19 Pfizer Inc. Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
US9937247B2 (en) 2016-02-23 2018-04-10 Maurizio Zanetti Universal cancer vaccine
AU2017336088B2 (en) * 2016-09-30 2023-07-06 Inovio Pharmaceuticals, Inc. Tert immunogenic compositions and methods of treatment using the same
FR3097123A1 (fr) * 2019-06-11 2020-12-18 Vaxon Biotech Combinaison de marqueurs pour prédire la réponse à Vx-001

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622952A (en) * 1983-01-13 1986-11-18 Gordon Robert T Cancer treatment method
US5030621A (en) * 1987-04-23 1991-07-09 Bystryn Jean Claude Shed melanoma antigen compositions
DE69023900D1 (de) * 1989-02-24 1996-01-11 Univ California Gentechnologisch veränderte immunglobuline.
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
IL106610A0 (en) * 1992-08-07 1993-12-08 Cytel Corp Hla binding peptides and their uses
KR960701988A (ko) * 1993-04-20 1996-03-28 윌리엄 에스. 로빈슨 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents)
US6106829A (en) * 1995-01-20 2000-08-22 Human Genome Sciences, Inc. Human prostatic specific reductase
US5658234A (en) * 1995-07-24 1997-08-19 J. D. Technologies, Inc. Method for treating tumors
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
AU3456099A (en) * 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
WO1999063945A2 (en) 1998-06-12 1999-12-16 Sloan-Kettering Institute For Cancer Research Vaccination strategy to prevent and treat cancers
US7030211B1 (en) * 1998-07-08 2006-04-18 Gemvax As Antigenic peptides derived from telomerase
EP1126872B1 (en) * 1998-10-29 2006-12-13 Dana-Farber Cancer Institute, Inc. CANCER IMMUNOTHERAPY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT
CA2368967A1 (en) 1999-04-09 2000-10-19 Biomira, Inc. Telomerase-specific cancer vaccine
FR2812087B1 (fr) * 2000-07-21 2007-05-11 Inst Nat Sante Rech Med Procede de criblage de peptides utilisables en immunotherapie
US7078491B1 (en) * 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
EP1356048A2 (en) * 2000-12-04 2003-10-29 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease

Also Published As

Publication number Publication date
WO2001060391A1 (en) 2001-08-23
US7388071B2 (en) 2008-06-17
JP2004527449A (ja) 2004-09-09
CA2399816A1 (en) 2001-08-23
US20090074741A1 (en) 2009-03-19
US8697836B2 (en) 2014-04-15
US20040086518A1 (en) 2004-05-06
WO2001060391A9 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
US8697836B2 (en) Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
Minev et al. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
Disis et al. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein
Relitti et al. Telomerase-based cancer therapeutics: a review on their clinical trials
Powell et al. Phenotypic and functional maturation of tumor antigen-reactive CD8+ T lymphocytes in patients undergoing multiple course peptide vaccination
Schreurs et al. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection
Adotevi et al. Immunogenic HLA-B* 0702-restricted epitopes derived from human telomerase reverse transcriptase that elicit antitumor cytotoxic T-cell responses
WO2002064057A2 (en) Use of cell penetrating peptides to generate antitumor immunity
CA2698079A1 (en) A cell therapy method for the treatment of tumors
RS65007B1 (sr) Vakcina u kombinaciji sa inhibitorom imunološke kontrolne tačke za primenu u lečenju kancera
Yamshchikov et al. Analysis of a natural immune response against tumor antigens in a melanoma survivor: lessons applicable to clinical trial evaluations
Vujanovic et al. Melanoma cancer vaccines and anti‐tumor T cell responses
Vonderheide et al. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy
Agarwal et al. Development of novel immune interventions for prostate cancer
JP2002512202A (ja) メラノーマの免疫治療用のワクチンアジュバント
CA2652310A1 (en) Human telomerase reverse transcriptase peptides
EP1257284A1 (en) A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
AU2006201968A1 (en) A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
Wagner et al. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo
Ostrand-Rosenberg et al. Immunologic targets for the gene therapy of cancer
Hersey et al. Melanoma vaccines
Himoudi et al. Development of anti-PAX3 immune responses; a target for cancer immunotherapy
Butterfield et al. DNA and dendritic cell-based genetic immunization against cancer
Offringa et al. T-cell mediated immunotherapy of cancer
Kosmatopoulos et al. and hTERT Cryptic Epitopes as neu HER-2